9. de Boeck 2017 ‐ treatment‐emergent and treatment‐related adverse events.

Event	400 mg mannitol (n = 87)	Control (n = 87)
Treatment‐emergent adverse events defined by MeDRa preferred term
Cough	14 (16.1%)	14 (16.1%)
Infective pulmonary exacerbation of cystic fibrosis	10 (11.5%)	14 (16.1%)
Headache	6 (6.9%)	7 (8.0%)
Nasopharyngitis	6 (6.9%)	6 (6.9%)
Lung infection	2 (2.3%)	5 (5.7%)
Treatment related AEs leading to withdrawal from the study
Dizziness	1 (1.1%)	0 (0%)
Cough	2 (2.3%)	0 (0%)
Oropharnygeal pain	1 (1.1%)	0 (0%)
Total number of AEs	114	117

Treatment emergent adverse events reported in de Boeck 2017 occurring in at least 5% of participants on either treatment